AxoGen (NASDAQ:AXGN - Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, November 7th. AxoGen has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company's earnings conference call can do so using this link.
AxoGen (NASDAQ:AXGN - Get Free Report) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%. The business had revenue of $47.91 million for the quarter, compared to analyst estimates of $43.27 million. On average, analysts expect AxoGen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
AxoGen Stock Down 3.0 %
NASDAQ:AXGN traded down $0.43 during mid-day trading on Thursday, hitting $14.02. The company had a trading volume of 183,823 shares, compared to its average volume of 397,231. The business has a fifty day simple moving average of $13.61 and a 200-day simple moving average of $9.78. The company has a current ratio of 3.51, a quick ratio of 2.32 and a debt-to-equity ratio of 0.70. AxoGen has a 1 year low of $3.45 and a 1 year high of $15.23. The firm has a market capitalization of $612.74 million, a price-to-earnings ratio of -28.42 and a beta of 1.13.
Analyst Upgrades and Downgrades
Several research firms have commented on AXGN. StockNews.com raised AxoGen from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. JMP Securities raised their target price on AxoGen from $17.00 to $20.00 and gave the company a "market outperform" rating in a research note on Friday, August 9th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $15.00.
Read Our Latest Analysis on AXGN
About AxoGen
(
Get Free Report)
AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.
Featured Stories
Before you consider AxoGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AxoGen wasn't on the list.
While AxoGen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
